Common Shares Outstanding: The number of class A shares currently held by investors.
Ligand Pharmaceuticals Incorporated (LGND) Common Shares Outstanding data is not available for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$59.67M |
|
$44.78M |
|
$2.99M |
|
$56.67M |
|
$45.82M |
|
$13.84M |
|
$42.94M |
|
$56.78M |
|
$34.72M |
|
$44.78M |
|
$44.78M |
|
$44.78M |
|
$18.06M |
|
$13.84M |
|
-- |
|
19.73M |
|
21.14M |
|
$2.27 |
|
$2.12 |
|
| Balance Sheet Financials | |
$832.27M |
|
-- |
|
$728.37M |
|
$1.56B |
|
$37.45M |
|
$446.19M |
|
$505.98M |
|
$543.42M |
|
-- |
|
$690.23M |
|
$1.02B |
|
|
Common Shares Outstanding |
-- |
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|